Boomerang Medical Secures $20M Series B to Advance First Pivotal Neuromodulation Trial for Ulcerative Colitis
核心洞察
Boomerang Medical (搜索) raised $20 million in Series B funding co-led by Arboretum Ventures (搜索) and Hatteras Venture Partners (搜索) to advance BOOM-IBD2, the first pivotal trial of implantable neuromodulation in inflammatory bowel disease (搜索).
The trial focuses on ulcerative colitis (搜索), a chronic autoimmune disease affecting millions in the U.S. and Europe, where no device-based treatment options currently exist.
The company's approach uses sacral neuromodulation, a therapy with over 500,000 procedures performed worldwide, to potentially reduce symptom burden and improve quality of life for ulcerative colitis (搜索) patients.
Boomerang Medical (搜索), a women-led bioelectronic medicine company, announced a $20 million Series B financing round co-led by Arboretum Ventures (搜索) and Hatteras Venture Partners (搜索). The funding will advance BOOM-IBD2, marking the first pivotal trial of implantable neuromodulation technology in inflammatory bowel disease (搜索), with an initial focus on ulcerative colitis (搜索).
The trial is currently enrolling patients at leading medical centers across the United States under clinical trial identifier NCT06571669. This represents a significant milestone in addressing treatment gaps for ulcerative colitis (搜索), the most common form of IBD that affects millions of people in the U.S. and Europe as a chronic autoimmune disease.
Novel Device-Based Approach for IBD Treatment
Boomerang Medical (搜索) is evaluating whether a small implanted device delivering gentle nerve stimulation through sacral neuromodulation can help address symptom burden in ulcerative colitis (搜索) patients. The field currently lacks any device-based treatment options, representing a significant unmet medical need.
The company's approach builds on the established safety profile of sacral neuromodulation, which has been performed in more than 500,000 procedures worldwide for other conditions. Boomerang completed a 40-patient feasibility study in both Crohn's disease (搜索) and ulcerative colitis (搜索), with results informing the design of their current pivotal trial.
"Ulcerative colitis (搜索) patients struggle with symptoms that profoundly affect their daily lives," said Heather Simonsen, CEO of Boomerang Medical (搜索). "Our pivotal trial asks a simple but critical question: can this therapy meaningfully reduce symptom burden and improve quality of life for people living with ulcerative colitis? With the continued support of our investors, we're pursuing that answer for patients and their physicians."
Industry Recognition and Clinical Significance
The Crohn's & Colitis Foundation (搜索) named Boomerang Medical (搜索) its "Emerging Leader in IBD," marking the first time a medical device company has received this recognition. This acknowledgment underscores the innovative potential of bioelectronic medicine approaches in autoimmune disease treatment.
Tom Shehab, MD, gastroenterologist and Managing Partner at Arboretum Ventures (搜索), emphasized the clinical need driving the investment. "There is a clear and significant unmet need for new approaches to help patients suffering from the debilitating symptoms of ulcerative colitis (搜索)," said Shehab, who also serves on Boomerang's Board of Directors. "We are impressed with the Boomerang team and their rigorous approach to clinical development. We are confident this financing will position them well to complete their pivotal trial and move this promising therapy forward."
Company Background and Mission
Headquartered on the campus of El Camino Hospital in Mountain View, California, Boomerang Medical (搜索) operates as a Company-In-Residence at Fogarty Innovation, described as the only healthcare-focused incubator of its kind in the United States. The company's mission centers on disrupting autoimmune disease treatment through bioelectronic medicine approaches.
The Series B funding round positions Boomerang Medical (搜索) to advance through their pivotal trial phase, potentially establishing the first device-based treatment option for ulcerative colitis (搜索) patients who currently rely solely on pharmaceutical interventions.